Tempus AI Inc. said it will acquire digital-pathology specialist Paige in a deal valued at about $81.25 million, paid predominantly in Tempus common stock. The transaction also includes Tempus assuming Paige’s remaining commitments under an existing Microsoft Azure cloud-services agreement. Founded in 2017, Paige holds nearly seven million digitised pathology slides drawn from 45 countries and developed the first FDA-cleared AI application in pathology. Tempus, which applies artificial intelligence to precision medicine, said the purchase will expand its dataset and technical team as it works on what it calls the largest oncology foundation model.